Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.972
-0.003 (-0.29%)
Dec 27, 2024, 4:00 PM EST - Market closed

Company Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.

The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.

It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies.

The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics, Inc.
Xilio Therapeutics logo
Country United States
Founded 2016
IPO Date Oct 22, 2021
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Rene Russo

Contact Details

Address:
828 Winter Street, Suite 300
Waltham, Massachusetts 02451
United States
Phone 857 524 2466
Website xiliotx.com

Stock Details

Ticker Symbol XLO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001840233
CUSIP Number 98422T100
ISIN Number US98422T1007
Employer ID 85-1623397
SIC Code 2834

Key Executives

Name Position
Dr. Rene Russo BCPS, Pharm.D. President, Chief Executive Officer and Director
Christopher Frankenfield Chief Operating Officer
Dr. Katarina Luptakova M.D. Chief Medical Officer
Kevin M. Brennan Senior Vice President of Finance and Accounting
Dr. Uli Bialucha Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Dec 19, 2024 SCHEDULE 13G/A Filing
Dec 19, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Sep 27, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 13, 2024 8-K Current Report